Coronary Syndrome
📧 Sign up to get email alerts when something new happens for Coronary Syndrome.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-08-23Clinical Trial Update: De-escalating Antiplatelet Therapy to Assess Platelet Reactivity and Outcomes in High Bleeding Risk Patients With Recent ACS [Phase 3]
A Phase 3 trial evaluating de-escalation of antiplatelet therapy to assess platelet reactivity and outcomes in high bleeding risk patients w…
-
FDA approval · 2023-07-24FDA Approved: TIROFIBAN HYDROCHLORIDE — Original Application (Nexus Pharmaceuticals LLC)
FDA approved the original application for tirofiban hydrochloride from Nexus Pharmaceuticals LLC, authorizing a generic tirofiban hydrochlor…
-
CLINICAL_TRIALS trial_result · 2023-07-14Clinical Trial Update: Escalated Single Platelet Inhibition for One Month Plus NOAC in Patients With Atrial Fibrillation and ACS Undergoing PCI [Phase 4]
Phase 4 trial evaluating escalated single platelet inhibition for one month plus a NOAC in patients with atrial fibrillation and acute coron…
-
FDA approval · 2023-06-08FDA Approved: CLOPIDOGREL — Supplemental Application (Aurobindo Pharma Limited)
FDA approves a supplemental application for a generic clopidogrel product from Aurobindo Pharma Limited.
-
CLINICAL_TRIALS trial_result · 2023-06-07Clinical Trial Update: Potential Drug Interactions With Bisoprolol in Egyptian Patients With ACS [Phase 2]
Phase 2 trial investigating potential drug interactions with bisoprolol in Egyptian patients with acute coronary syndrome has completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2023-06-07Clinical Trial Update: Pharmacogenetic Study of Bisoprolol in Egyptian Patients With Acute Coronary Syndrome [Phase 2]
A Phase 2 pharmacogenetic study of bisoprolol in Egyptian patients with acute coronary syndrome has been completed.
-
FDA approval · 2023-05-25FDA Approved: EPTIFIBATIDE — Supplemental Application (Eugia US LLC)
FDA approved a supplemental application for the generic drug Eptifibatide filed by Eugia US LLC (ANDA 206127).
-
FDA approval · 2023-05-01FDA Approved: TIROFIBAN — Original Application (Eugia US LLC)
The FDA approved Eugia US LLC's original Abbreviated New Drug Application for tirofiban, granting approval of a generic version of the anti-…
-
CLINICAL_TRIALS trial_result · 2023-04-26Clinical Trial Update: De-escalation of Ticagrelor in Post PPCI [Phase 1, Phase 2]
A clinical trial update on de-escalation of ticagrelor after primary percutaneous coronary intervention, spanning Phase 1 and Phase 2.
-
CLINICAL_TRIALS trial_result · 2023-04-24Clinical Trial Update: Optimal Antithrombotic Therapy for ACS Patients Concomitant With AF and Implanted With New-generation DES (OPTIMA-3, 4) [Phase 4]
Phase 4 trial update evaluating optimal antithrombotic therapy for acute coronary syndrome patients with non-valvular atrial fibrillation wh…
-
CLINICAL_TRIALS trial_result · 2023-04-24Clinical Trial Update: MBCT Delivered Via Group Videoconferencing for ACS Syndrome Patients With Depressive Symptoms [NA]
Clinical trial update on MBCT delivered via group videoconferencing for patients with acute coronary syndrome and depressive symptoms; statu…
-
CLINICAL_TRIALS trial_result · 2023-04-21Clinical Trial Update: Evaluation of Safety and Efficacy of Two Ticagrelor-based De-escalation Antiplatelet Strategies in Acute Coronary Syndrome [Phase 3]
Phase 3 trial evaluating safety and efficacy of two ticagrelor-based de-escalation antiplatelet strategies in acute coronary syndrome.
-
FDA approval · 2023-04-21FDA Approved: TICAGRELOR — Original Application (Ascend Laboratories, LLC)
FDA approved Ticagrelor under an Original Application by Ascend Laboratories, LLC. The approval supports its use as an antiplatelet therapy …
-
FDA approval · 2023-04-12FDA Approved: PRASUGREL — Supplemental Application (Accord Healthcare Inc.)
FDA approved a supplemental application for the generic prasugrel from Accord Healthcare Inc., finalizing a regulatory action under the ANDA…
-
CLINICAL_TRIALS trial_result · 2023-03-23Clinical Trial Update: Assessment of Acute Disease to Reduce Imaging Costs [NA]
Completed clinical trial assessing acute disease to reduce imaging costs, with results posted.
-
FDA approval · 2023-02-23FDA Approved: EPTIFIBATIDE — Supplemental Application (Mylan Institutional LLC)
FDA approved a supplemental application for the generic Eptifibatide from Mylan Institutional LLC. The approval updates the product's regula…
-
FDA approval · 2023-02-07FDA Approved: TIROFIBAN HYDROCHLORIDE — Original Application (Nexus Pharmaceuticals LLC)
FDA approved the original ANDA for tirofiban hydrochloride from Nexus Pharmaceuticals LLC.
-
CLINICAL_TRIALS trial_result · 2023-02-06Clinical Trial Update: Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome [Phase 4]
A Phase 4 randomized trial comparing ticagrelor to prasugrel in patients with acute coronary syndrome has completed.
-
CLINICAL_TRIALS trial_result · 2023-01-17Clinical Trial Update: The Safety and Efficacy Of Rivaroxaban and Ticagrelor for Patients With Atrial Fibrillation After Percutaneous Coronary Intervention [Phase 3]
A Phase 3 trial updating safety and efficacy of rivaroxaban plus ticagrelor in patients with atrial fibrillation after percutaneous coronary…
-
CLINICAL_TRIALS trial_result · 2023-01-04Clinical Trial Update: Mono Antiplatelet and Colchicine Therapy [Phase 4]
Phase 4 clinical trial evaluating mono antiplatelet and colchicine therapy in patients with acute coronary syndrome and after drug-eluting s…
-
FDA approval · 2022-11-15FDA Approved: ENOXAPARIN SODIUM — Supplemental Application (Amphastar Pharmaceuticals, Inc.)
FDA approves Amphastar Pharmaceuticals' supplemental application for enoxaparin sodium.
-
CLINICAL_TRIALS trial_result · 2022-11-04Clinical Trial Update: Safety, Pharmacokinetic Study of RVX000222 in Healthy Subjects and Subjects With Low HDL Cholesterol [Phase 1, Phase 2]
Phase 1/2 safety and pharmacokinetic study of RVX000222 in healthy subjects and individuals with low HDL cholesterol completed.
-
CLINICAL_TRIALS trial_result · 2022-10-27Clinical Trial Update: The POST-ACS Study [Phase 4]
A Phase 4 clinical trial update for the POST-ACS study, involving patients with diabetes mellitus and acute coronary syndrome, with status c…
-
CLINICAL_TRIALS trial_result · 2022-10-12Clinical Trial Update: Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS [Phase 3]
Phase 3 trial update evaluating dalcetrapib versus placebo in a genetically defined population with recent acute coronary syndrome; study co…
-
CLINICAL_TRIALS research · 2022-10-10Clinical Trial Update: To Assess the Efficacy and Safety of Dual Anticoagulants i.e. Rivaroxaban Plus Aspirin and Clopidogrel Plus Aspirin in Patients Suffering From an Acute Coronary Syndrome [Phase 4]
Phase 4 trial update evaluating the efficacy and safety of dual antithrombotic regimens (rivaroxaban plus aspirin and clopidogrel plus aspir…